


Gene and Vaccine for Life

# Genexine

Investor Relations 2022



# Disclaimer

---

This Presentation has been prepared by Genexine Inc. for the purpose of setting out certain confidential information in respect of Genexine's business activities and strategy. References to this Presentation include any information which has been or may be supplied in writing or orally in connection with this Presentation or in connection with any further inquiries in respect of this Presentation. This Presentation is for the exclusive use of the recipients to whom it is addressed.

This Presentation and the information contained herein may be confidential. In addition to the terms of any confidentiality undertaking that a recipient may have entered into with Genexine, by its acceptance of this Presentation, each recipient agrees that it will not, and it will procure that each of its agents, representatives, advisors, directors or employees (collectively, "Representatives"), will not, and will not permit any third party to, copy, reproduce or distribute to others this Presentation, in whole or in part, at any time without the prior written consent of Genexine, and that it will keep confidential all information contained herein not already in the public domain and will use this Presentation for the sole purpose of setting out [familiarizing itself with] certain limited background information concerning Genexine and its business strategy and activities. This Presentation is not intended to serve as basis for any investment decision. If a recipient has signed a confidentiality undertaking with Genexine, this Presentation also constitutes Confidential Information for the purposes of such undertaking.

While the information contained in this Presentation is believed to be accurate, the Preparers have not conducted any investigation with respect to such information. The Preparers expressly disclaim any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this Presentation or any other written or oral communication transmitted to any interested party in connection with this Presentation so far as is permitted by law. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, estimates, forecasts, analyses or forward looking statements contained in this Presentation which involve by their nature a number of risks, uncertainties or assumptions that could cause actual results or events to differ materially from those expressed or implied in this Presentation. Only those particular representations and warranties which may be made in a definitive written agreement, when and if one is executed, and subject to such limitations and restrictions as may be specified in such agreement, shall have any legal effect. By its acceptance hereof, each recipient agrees that none of the Preparers nor any of their respective Representatives shall be liable for any direct, indirect or consequential loss or damages suffered by any person as a result of relying on any statement in or omission from this Presentation, along with other information furnished in connection therewith, and any such liability is expressly disclaimed.

Except to the extent otherwise indicated, this Presentation presents information as of the date hereof. The delivery of this Presentation shall not, under any circumstances, create any implication that there will be no change in the affairs of Genexine after the date hereof. In furnishing this Presentation, the Preparers reserve the right to amend or replace this Presentation at any time and undertake no obligation to update any of the information contained in this Presentation or to correct any inaccuracies that may become apparent.

This Presentation shall remain the property of Genexine. Genexine may, at any time, request any recipient, or its Representatives, shall promptly deliver to Genexine or, if directed in writing by Genexine, destroy all confidential information relating to this Presentation received in written, electronic or other tangible form whatsoever, including without limitation all copies, reproductions, computer storage devices or written materials which contain such confidential information. At such time, all other notes, analyses or compilations constituting or containing confidential information in the recipient's, or their Representatives', possession shall be destroyed. Such destruction shall be certified to Genexine by the recipient in writing.

Neither the dissemination of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Preparers or any of their respective affiliates to enter any contract or otherwise create any legally binding obligation or commitment. The Preparers expressly reserve the right, in their absolute discretion, without prior notice and without any liability to any recipient to terminate discussions with any recipient or any other parties.

This Presentation does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in Genexine, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares in Genexine.


No securities commission or regulatory authority in any country has in any way opined upon the accuracy or adequacy of this Presentation or the materials contained herein. This Presentation is not, and under no circumstances is to be construed as, a prospectus, a public offering or an offering memorandum as defined under applicable securities laws and shall not form the basis of any contract.

The distribution of this Presentation in certain jurisdictions may be restricted by law and, accordingly, recipients of this Presentation represent that they are able to receive this Presentation without contravention of any unfulfilled registration requirements or other legal restrictions in the jurisdiction in which they reside or conduct business.

# 01 Genexine at a glance

## hyFc™

(Long-acting protein drugs)



Long-acting platform technology which can be applied to various APIs, and maximize protein sustainability.

## DNA vaccine











(Cancer therapeutic/ Infectious disease)



Therapeutic + Preventive DNA vaccine platform with strong T cell immunity.

- ◆ A distinguished Korean biotech company with various First-in-Class & Best-in-Class pipelines based on 2 platforms.
- ◆ On going 3 Global Phase 3 trials, aiming for 7 BLA submissions within 5 years.
- ◆ Possible Sub L/O and royalty income from licensee + additional L/O of major pipelines.
- ◆ Win-Win strategy with partners by collaboration studies & holding stock shares, aiming for IPO.

# 02 Clinical Development Status

| pipeline   | indication                            | Clinical development phase |         |                 | sponsor              | collaborator   |
|--|---------------------------------------|----------------------------|---------|-----------------|----------------------|--|
|  |                                       | Phase 1                    | Phase 2 | Phase 3         |                      |  |
|  <b>GX-E4</b><br>(long-acting EPO)            | CKD-induced Anemia                    | Phase 2 in KR              |         | Phase 3 in Asia | KG Bio               | Genexine   |
|  <b>GX-H9</b><br>(long-acting growth hormone) | Growth Hormone Deficiency (Pediatric) | Phase 2 in KR/EU           |         | Phase 3 in CN   | Handok, I-MAB        | Genexine   |
|  | Growth Hormone Deficiency (Adult)     | Phase 2 in KR/EU           |         |                 | Genexine, Handok     |  |
|  <b>GX-19N</b>                                | COVID-19 Vaccine booster shot         | Phase2a in KR              |         | Phase2/3 Global | Genexine, Kalbe      |  |
|  <b>GX-I7</b>                                 | TNBC, GBM, High risk Skin cancer      | Phase 1~2 in KR/US/CN      |         |                 | Genexine, NIT, I-Mab |  <b>MERCK</b>  <b>Roche</b><br> Bristol Myers Squibb™ |
|  | COVID-19 treatment                    | Phase 2 in Indonesia       |         |                 | Genexine, KG Bio     |  |
|  <b>GX-188E</b>                             | Cervical cancer                       | Phase 2 in KR              |         |                 | Genexine             |  <b>MERCK</b>   |
|  <b>GX-G3</b>                               | Neutropenia                           | Phase 2 in EU              |         |                 | Genexine, Ilkogen    |  |

Completed

On-going



---

# GX-E4

Long-acting EPO  
Best-in-Class Products



# 03 Phase 3 : GX-E4 (Long-acting EPO)

## EPO(Erythropoietin) Anemia treatment


| 1 <sup>st</sup> Gen                    | 2 <sup>nd</sup> Gen | 3 <sup>rd</sup> Gen |
|--|---------------------|---------------------|
| 3 shots/wk                             | 1 shot/wk           | Bi-weekly/monthly   |
| Epogen(Amgen)                          | Aranesp(Amgen)      | Mircera(Roche)      |
| Unmet needs<br>Sustainability & safety |                     |                     |

## Clinical Trials

- **Phase 3 trial in multi-nations (2020 March~)**
  - CKD-induced Anemia (non-dialysis )
  - 7 countries: Korea, Austrailia, Taiwan, Indonesia, Malaysia, Philiphines, Thailand.
  - Recruited 327 / 386(Dec. '21)
  - Non-inferiority study against Mircera

## Competitiveness

Long-acting EPO drug with superior sustainability, efficacy, safety and **price competitiveness**



**No mutation**

### Outstanding efficacy and safety

- High activity and efficacy
- Safely treat patients without hypersensitive immune reaction nor adverse events.

### Price competitiveness

- Simplified production process
- Price competitive due to low mfg. cost

### Superior sustainability

- Bi-weekly or monthly dose

# 04 GX-E4 (Long-acting EPO) Business Structure

Early stage development

Global development


Global market




# 05 GX-E4 (Long-Acting EPO) Market & Competitive Landscape

- Over 60% of Global CKD Anemia market consisted of major market such as US, EU.
- ESA(Erythropoiesis Stimulating Agent) market expected \$2.9B in 2029

## Global CKD Anemia treatment market expectation



## Global CKD Anemia treatment market 2027



Reference: IMS(~2017) + Global Data(HIF-PHi) + Roche Data Base + VIFOR annual report + Amgen annual report





---

# GX-H9

Long-acting Growth Hormone  
Best-in-Class Products

# 06 Phase 3 : GX-H9 (Long-Acting Growth Hormone Deficiency Treatment)

## AGHD and PGHD

### Growth Hormone Deficiency Treatment

#### Daily Injection

312 ~ 365 shots/year

#### Weekly/Bi-weekly injection

Weekly : 52 shots/year  
Bi-weekly : 26 shots/year

**Clinical Unmet Needs**  
**Long-Acting & Convenience**


## Clinical Trials

- **Ph3 Trial in China by I-Mab**
  - Ph3 approval: 2020 Oct.
  - FPI: 2021 Feb.
  - BLA: 2023 first half
  - Recruit: 114/165 recruited
  - **US & EU ODD**


## Growth data comparison, 1<sup>st</sup> yr vs 2<sup>nd</sup> average growth

- **Weekly or bi-weekly based injection** clinical data for 5 to 12 yrs-old growth hormone deficiency patients.
- Growth rate continued in 2<sup>nd</sup> yr compared to 1<sup>st</sup> yr. (both weekly and bi-weekly)
- Growth rate continued even after switching to H9 2<sup>nd</sup> yr after injection of other growth hormone product during 1<sup>st</sup> yr. (both weekly and bi-weekly)
- Developing pen type injector for better convenience.

### aHV at 1<sup>st</sup> and 2<sup>nd</sup> year by doses




### Switching to GX-H9 at 1 year



\* EOW : Every Other Week




# 07 GX-H9 Business Structure



# 08 GX-H9 Market & Competitive Landscape

- Pediatric growth hormone deficiency treatment, global market expected \$6.0 B (CAGR6.4%) in 2030.
- Chinese pediatric growth hormone deficiency treatment market expected \$3.2B (CAGR 15.7%) in 2030, 60% share of global market

Reference : F&S, CMBIS

| Company                 |  |  |   |  |  |  |
|-------------------------|---|--|---|---|---|---|
| Product                 | GX-H9   | TransCon hGH   | somatrogon  | somapacitan   | Jintrolong®   | Xiamen Amoytop Biotech  |
| Frequency               | Weekly<br>Twice-monthly   | Weekly   | Weekly  | Weekly  | Weekly  | Weekly  |
| Stage                   | CN, Phase 3   | US, Marketed ('21.8)<br>CN, Phase 3  | US, BLA submission  | US, Phase 3   | CN, Marketed  | CN, Phase 2/3   |
| Orphan Drug Designation | FDA: Nov. 2016<br>EMA: July 2021  | FDA: Apr. 2020<br>EMA: Oct. 2019   | FDA: Sep. 2010<br>EMA: Jan.2013   | EMA: Aug. 2018  | -   | -   |
| # of Patients           | n=165   | n=150  | n=224   | n=200   | n=1500  | n=400   |
| Height Velocity         | 11.76cm/yr<br>(1.2mg/kg)  | 11.2cm/yr<br>(0.24mg/kg )  | 10.12cm/yr<br>(0.66mg/kg)   | 11.5cm/yr<br>(0.16mg/kg )   | 2.26±0.87cm ~<br>13.41±3.72cm/yr<br>(0.2mg/kg)                                      | -   |





---


GX-188E

Papitrol-188

DNA vaccine for HPV infection

# 09 GX-188E : Therapeutic DNA Vaccine

- Plasmid DNA based immunogenetic therapeutic vaccine. Injecting therapeutic gene to induce immune response against specific antigen.
- Intra-muscular injection via electroporator for maximizing delivery of DNA vaccine into the nucleus of muscle cells.
- Selective induction of immune response of T cells to HPV (human papilloma) 16/18 virus-specific antigen, which accounts for more than 70% of cervical cancer causes.
- Maximize the effect when administered in combination with immune checkpoint inhibitors




## Clinical Tirals

| indication           | 2018 | 2019                            | 2020    | 2021 | 2022                                  | 2023 |
|----------------------|------|---------------------------------|---------|------|---------------------------------------|------|
| Cervical cancer      |      | Phase 1                         | Phase 2 |      |                                       |      |
|                      |      | MFDS announced 'Bio-Challenger' |         |      | Targeting conditional approval in KOR |      |
| Head and neck cancer |      |                                 |         |      | Phase 2                               |      |



# 10 GX-188E Business Structure



# 11 GX-188E High Efficacy and Safety Results

- Interim analysis reported at ASCO 2021, results from ph2 for combination with Keytruda (KEYNOTE-567)
- **33 % ORR (16/48) with 6 CR and 10 PR.**
- 48.0% (12/25) ORR under condition of PD-L1 + patients, HPV 16 and SCC(squamous cell carcinoma).
- High safety and tolerability: similar AE level compared to Keytruda mono.

## Ph2 Interim Result

| ORR<br>N (%) | Safety<br>set<br>(N=51) | Efficacy<br>set <sup>a</sup><br>(N=48) | PD-L1 status <sup>b</sup> |                       | HPV type           |                               | Cell type        |                 |
|--------------|-------------------------|--|---------------------------|-----------------------|--------------------|-------------------------------|------------------|-----------------|
|              |                         |  | Positive<br>(N=36/38)     | Negative<br>(N=12/13) | HPV16<br>(N=34/36) | HPV18 or<br>both<br>(N=14/15) | SCC<br>(N=36/38) | AC<br>(N=12/13) |
| CR           | 6 (11.8)                | 6 (12.5)                               | 6 (16.7)                  | 0 (0.0)               | 6 (17.6)           | 0 (0.0)                       | 6 (16.7)         | 0 (0.0)         |
| PR           | 10 (19.6)               | 10 (20.8)                              | 9 (25.0)                  | 1 (8.3)               | 6 (17.6)           | 4 (28.6)                      | 6 (16.7)         | 4 (33.3)        |
| SD           | 8 (15.7)                | 8 (16.7)                               | 7 (19.4)                  | 1 (8.3)               | 6 (17.6)           | 2 (14.3)                      | 7 (19.4)         | 1 (8.3)         |
| PD           | 26 (51.0)               | 24 (50.0)                              | 14 (38.9)                 | 10 (83.4)             | 16 (47.2)          | 8 (57.1)                      | 17 (47.2)        | 7 (58.4)        |
| NE           | 1 (1.9)                 | -                                      | -                         | -                     | -                  | -                             | -                | -               |
| BORR         | 16 (31.4)               | <b>16 (33.3)</b>                       | 15(41.7/39.5)             | 1 (8.3/7.7)           | 12(35.3/33.3)      | 4 (28.6/26.7)                 | 12(33.3/31.6)    | 4(33.3/30.8)    |
| DCR          | 24(47.1)                | 24 (50.0)                              | 22(61.1/57.9)             | 2 (16.7/15.4)         | 18(52.9/50.0)      | 6 (42.9/40.0)                 | 9(52.8/50.0)     | 5(41.7/38.5)    |

### Keytruda mono

(KEYNOTE-158, N=98)

Total ORR : 12.2%

PD-L1-positive : ORR 14.6%


PD-L1-negative : 0%

---

# GX-19N

## SARS-CoV-2

### DNA Vaccine




# 12 GX-19N: The Next Generation COVID-19 Vaccine

- DNA vaccine, safest and protect from COVID-19 variants.




## COVID-19 Vaccine with Broad Immune Responses



|                |   |
|----------------|---|
| Antigen        | <ul style="list-style-type: none"><li>• <b>Plasmid DNA for protection against variants:</b> Spike + Nucleocapsid proteins of SARS-CoV-2</li></ul>   |
| Immunogenicity | <ul style="list-style-type: none"><li>• <b>Strong and Broad T cell immunity and enhanced nAB response.</b><br/>:Nucleocapsid protein, more conserved and highly immunogenic (<i>J Virol</i>, 94(13):e00647-20 (2020))</li></ul> |
| Safety         | <ul style="list-style-type: none"><li>• <b>High safety of DNA vaccine platform</b></li></ul>  |
| Stability      | <ul style="list-style-type: none"><li>• Stored and distributed at room temperature for 3 month or Up to 36 months at 2~8°C</li></ul>  |
| Injection      | <ul style="list-style-type: none"><li>• IM with electroporator</li></ul>  |

# 13 GX-19N Booster Shot Vaccine Development Plan

## GX-19N booster shot



- Amended recruitment from non-vaccinated healthy adults to Sinovac/Sinopharm vaccinated for booster shot clinical trial
- **‘Booster vaccine for protection against breakthrough infection’**
- DNA vaccine platform’s high safety least worries for clinical adverse events considering annual re-vaccination.

| Development Timeline           |  |
|--------------------------------|--|
| Ph1/2a IND approval            | • 2020.12.11   |
| Ph1, N=20                      | • 2020.12 ~ (FPI 2020.12.30)   |
| Ph2a, N=150                    | • 2021.02 ~ (FPI 2021.02.26)   |
| Ph2/3 IND approval             | • 2021.07.07   |
| Ph2/3 IND amendment submission | <ul style="list-style-type: none"><li>• Amended and applied for booster shot IND at Indonesia &amp; Argentina</li><li>• N=1,000 → 14,000 expansion planned</li><li>• Planning for expansion to booster shot study for other vaccine platforms.</li></ul> |

# 14 Unmet Needs : Vaccine Issues to be Considered Post-pandemic

- Shortage of vaccine efficacy, short duration and variants avoiding nAb, increased the needs of T cell vaccine

## Efficacy to Variants

- Vaccine induced nAb 70-100-folds decreased against S.Africa variant(B.1.351)


|        | Efficacy to symptoms |                       |
|--------|----------------------|-----------------------|
|        | Global ph3           | SA variant            |
| AstraZ | 62%                  | 22% (10%)             |
| NVX    | 96%                  | 49% (NA) <sup>3</sup> |
| J&J    | 66%                  | 57% (NA) <sup>4</sup> |

- Targeting Spike & Nucleocapsid protein, stronger and broad T cell response to protect against variants.

| Protein      | # of T cell epitopes |         |
|--------------|----------------------|---------|
|              | in Spike             | # in NP |
| HLA-class I  | 248                  | 60      |
| HLA-class II | 154                  | 32      |

## Safety

- Approved vaccines showed moderate and severe clinical adverse events.
- GX-19N only reported Mild AE with no moderate & severe AE cases → high safety



## Duration


- The efficacy duration of nAb is only 3 to 6 mths but T cell can be much longer than nAb.
- T cell plays a major role in preventing COVID19 in case humoral immunity is not enough.
- Convalescent COVID19 patients have T cell that has memorized COVID19 virus which will be re-activated when the virus is re-introduced.
- T cell immunity reportedly stays 17 years against SARS-CoV which has 75% genetic similarity to COVID19.




# 15 COVID-19 Vaccines Market Forecast

- The top 15 major COVID-19 vaccines markets are expected to reach \$20B in 2027 after peak sales of \$70B in 2021.
- The needs of revaccination and booster shot due to breakthrough infections and new variants expected to be market driver after 2022.
- Emerging markets (LATAM, MENA, China, SE Asia) take 65% of potential vaccine market share in which Sinovac and Sinopharm killed vaccines have been distributed.

## Sales Forecast of 15 Vaccines (2020~2027F)




## High unmet needs for booster shots



### Sinovac (PiCoVacc)

#### Contracts

- Apprx. 53 countries
- 1B doses



### Sinopharm (BBIBP/Wuhan)

#### Contracts

- apprx. 33 countries
- Over 700M doses

GlobalData COVID-19 Dashboard 2021. Sep.




---

**GX-I7** (efineptakin alfa )

Long acting Interleukin-7  
(IL-7-hyFc)

Lymphopenia Correction

# 16 GX-I7: The First Long-acting Lymphopenia Correction Drug Candidate



Higher protein stability




Higher productivity



Longer *in vivo* half-life

## T cell Amplifier

Interleukin-7  
Long-acting Interleukin-7



## T cell Activator

- Cancer vaccine
- IL-2, IL-15, IFN-alpha
- CD137 L, OX40 L, ICOSL
- TLR agonists, etc

## T cell Suppressor blockade

- anti-PD-1, anti-PD-L1
- anti-CTLA4
- anti-TIM-3, anti-TIGIT
- anti-TGF-beta

# 17 GX-I7: Unlimited potential with Combination Therapies

- Combo trial with various partners targeting the world oncology market: expecting sub-licensing, milestones, royalty incomes.
- Genexine holds Korea and Japan rights, targeting additional LO

## EU & North, South America

NEOIMMUNETECH

2015 GX-I7 L/O

35% of Sub-license out or 35% of sales profit

21% share holder

|      |            |  |                                    |
|------|------------|--|------------------------------------|
| Mono | -          | GBM (n=75)   | Phase 1 (NIT-104, Single dose)     |
| COM  | Temozol    | GBM (n=46)   | Phase 1/2 (NIT-107)                |
| COM  | Tecentriq® | High risk skin cancer  | Phase 1b/2a (NIT-106)              |
| COM  | KEYTRUDA®  | TNBC, NSCLC, SCLC, Pancreatic, Colorectal and ovarian cancer | Phase 1b/2a (NIT-110), KEYNOTE-A60 |
| COM  | Opdivo®    | Gastric, GEJ, and Esophageal Adenocarcinomas                 | Phase 2 (NIT-109)                  |
| COM  | Tecentriq® | Non-Small Cell Lung Cancer (1L)                              | Phase 2 (NIT-119)                  |
| Mono | -          | Recurrent SCCHN  | Phase 1 (NIT-115)                  |
| Mono | -          | Kaposi Sarcoma   | Phase 1 (NIT-108)                  |
| COM  | Kymriah®   | Diffuse large B-cell lymphoma                                | Phase 1b (NIT-112)                 |

Genexine

## Korea

|     |           |                 |            |
|-----|-----------|-----------------|------------|
| COM | KEYTRUDA® | Recurrent mTNBC | Phase 1b/2 |
| COM | Avastin®  | Recurrent GBM   | Phase 2    |

## Greater China



2017 L/O, Oncology indications only. total \$560M (upfront\$10M) plus royalty and milestone payments.

|      |         |                 |                     |
|------|---------|-----------------|---------------------|
| Mono | -       | Solid Tumor     | Phase 1/2a (STM101) |
| COM  | Temozol | GBM             | Phase 2 (GBM201)    |
| COM  | Pembro  | TNBC, HNSCC etc | Phase 2 9STM202)    |

## ASIA/ Oceania / Africa / Middle East




2021 L/O total \$1.2B (upfront \$30M)  
10% royalty plus milestone payments.

|      |                    |                            |         |
|------|--------------------|----------------------------|---------|
| Mono | Standard treatment | COVID-19 infected patients | Phase 2 |
|------|--------------------|----------------------------|---------|

# 18 GX-I7 Market & Competitive Landscape

- Other blood cell targeting drugs formed \$multi-billion market. **Yet, still no drugs developed for lymphopenia correction.**

## Versatile Combination Potential in Cancer Immunotherapy



**GX-I7**  
T-cell amplifier

**Combination**



**Checkpoint Inhibitor**(Anti-PD-1, Anti-PD-L1..)  
\$ 57bn Global Market in 2025

**Cell Therapy (CAR-T / TCR-T)**  
\$ 9bn Global Market in 2025

**Chemotherapy & Radiotherapy**  
\$ 33bn Global Market in 2020

**Cancer Vaccines (DNA, RNA Peptide, Viral)**  
\$ 12bn Global Market in 2025

**Infectious Disease Therapy**  
\$ 59bn Global Market in 2026

(Source : EvaluatePharma World Preview 2020, Mckinsey&Company, , MarketWatch 2020)




# 19 GX-I7(NT-I7) : High Safety & Efficacy for mTNBC

- Interim analysis reported (KEYNOTE-899) at SITC in November 2020 (indication: recurrent mTNBC)- Combination therapy (GX-I7 with Keytruda)
- 1,200ug/kg dose of GX-I7 combo with Keytruda in the next Ph2 study - ORR 27.8 %
- SITC 2021 Interim analysis: GBM Ph1b Combo with Chemo & colorectal cancer Ph2a Keytruda Combo. (NT-I7)

## Ph2 Interim Result

| Response<br>(RECIST v1.1)<br>N (%) | GX-I7/Pembrolizumab<br>Simultaneous Treatment<br>(N=36) |              |                |                |
|------------------------------------|---|--------------|----------------|----------------|
|                                    | 720<br>µg/kg  | 960<br>µg/kg | 1,200<br>µg/kg | 1,440<br>µg/kg |
| ORR                                | 1 (16.7)  | 1 (16.7)     | 5 (27.8)       | -              |
| CR                                 | -   | -            | -              | -              |
| PR                                 | 1 (16.7)  | 1 (16.7)     | 5 (27.8)       | -              |
| SD                                 | 1 (16.7)  | 2 (33.3)     | 3 (16.7)       | 1 (16.7)       |
| PD                                 | 4 (66.7)  | 3 (50.0)     | 10 (55.6)      | 5 (83.3)       |
| DCR                                | 3 (50.0)  | 4 (66.7)     | 8 (44.4)       | 1 (16.7)       |

Source: SITC 2020 Poster Presentation







---

# Business Strategy

# 20 Global Partnership (1)

## Korea

## Global

Listed

NEOIMMUNETECH

ToolGen

GenNBio  
(주)제넨바이오

21.2%

880 M\$

14.2%

810 M\$

7.2%

\$150M

I-MAB  
BIOPHARMA

REZOLUTE

I-Mab  
4.6%

\$3.7B

Rezolute  
11.7%

\$73.8M

Genexine

OPEN  
INNOVATION

Genexine holds share of listed companies  
apprx. \$500M

Unlisted

SL Pogen  
63.6%

Ajinomoto-  
Genexine  
25%

SL Vaxigen  
13.5%

Innopeutics  
8.3%

Curogen  
6.2%

Ybiologics  
1.4%

ILKOGEN  
50%

Turkey

KinGen  
Biotech  
50%

Thailand

Simnogen  
49%

China

Colimmune  
25.8%

USA

KG-Bio  
20.3%

Indonesia

Egret  
Therapeutics  
5.9%

USA

(As of Nov. 19, 2021)

# 21 Global Partnership (2)


## License-out Status

| Contract Date | Partner Company | Product                  | Territory                  | Total                                 |
|---------------|-----------------|--------------------------|----------------------------|---------------------------------------|
| 2014.07       | BSK             | GX-188E                  | China                      | \$ 5.0mn                              |
| 2015.06       | NeoImmuneTech   | GX-I7                    | Europe/USA                 | \$ 12.5mn                             |
| 2015.10       | I-Mab(Tasgen)   | GX-H9, GX-G6, GX-G3 etc. | China                      | \$ 100.0mn                            |
| 2016.02       | CWB             | GX-E4                    | China                      | \$ 44.5mn                             |
| 2016.03       | KG BIO          | GX-E4                    | ASEAN                      | \$ 3.0mn                              |
| 2017.12       | I-Mab           | GX-I7                    | China                      | \$ 560.0mn                            |
| 2020.01       | GENBIO          | GX-P1, GX-P10            | Worldwide                  | \$ 173.6mn                            |
| 2020.12       | Turret Capital  | GX-P1                    | Worldwide                  | Egret Therapeutics 5% share + \$200mn |
| 2021.02       | KG BIO          | GX-I7                    | ASEAN, MENA, Oceania, etc. | \$ 1,100.0mn                          |

License out total \$2.2 B


## 22 Genexine's Open Innovation - L/O and Strong Partnership

- Win-Win strategy with L/O partner companies: shareholding leads to building of strong partnership
- As development stage advances, L/O deal size and company value of partners increase



# 23 Genexine's Open Innovation : Co-development Strategy








- 6 independent + 18 collaboration = Total 25 trials currently in clinical development
- Compared to 2015, # of clinical studies increased by 3.5-folds
- R&D expenses kept approximately \$ 40mn since 2017






# 24 BLA Submission Plan

- Expecting 7 products' BLA submission within 5 years

| 2023   |   | 2022/2023  |   | 2023/2024   |   | 2024/2025   |
|--|---|--|---|---|---|---|
| <b>GX-19</b><br>(conditional approval)   | <b>GX-I7</b><br>(conditional approval)  | <b>GX-188E</b><br>+Keytruda®<br>(conditional approval)                             | <b>GX-I7 (NT-I7)</b><br>+Keytruda®<br>(conditional approval)                        | <b>GX-E4</b>  | <b>GX-H9</b>  | <b>GX-I7(NT-I7,TJ107)</b><br>+Temozolomide  |
|  |  |  |  |  |  |  |
| COVID-19<br>DNA Vaccine  | COVID-19<br>Treatment   | Cervical cancer  | CRC/PaC/<br>TNBC/GBM  | CKD-induced<br>Anemia   | Growth Hormone<br>Deficiency  | GBM   |
| Current clinical Phase   |   |  |   |   |   |   |
| Phase2/3<br>(Global)   | Phase2<br>(Indonesia)   | Phase2<br>(Korea)  | Phase2<br>(Korea/US)  | Phase3<br>(Asia)  | Phase3<br>(China)   | Phase3<br>(China)   |

# 25 Investment Highlights: "It's just beginning..."



The background of the slide is a 3D rendering of numerous metallic, reflective spheres connected by thin, cylindrical rods. These elements are arranged in a complex, overlapping pattern that creates a sense of depth and movement, resembling a molecular structure or a network of interconnected nodes.

# THANK YOU

**Genexine, Inc.**

Korea Bio Park, Bldg. B,  
700 Daewangpangyo-ro, Bundang Gu,  
Seongnam Si, Gyeonggi Do, 463-400 Korea

**Contact**

IR/PR

[Jongsoo.lee@genexine.com](mailto:Jongsoo.lee@genexine.com)

+82-31-628-2274